MRD levels and patient characteristics in patients with MRD <10−5 who subsequently developed disease progression
| MRD level . | IGHV-MS . | B2M (mg/L) . | ZAP70 . | FISH subtype . |
|---|---|---|---|---|
| 0.98 × 10−6 detectable | Unmutated | 3.1 | Positive | Negative |
| 0.90 × 10−6 detectable | Unmutated | 5.9 | Positive | Del(11q) |
| Undetectable (limit of detection 1.9 × 10−6) | Unknown | 7.7 | Positive | Trisomy 12 |
| 6.78 × 10−6 | Unmutated | 3.1 | Unknown | Trisomy 12 |
| 5.30 × 10−6 | Unmutated | 3.1 | Positive | Del(11q) |
| 1.87 × 10−6 | Mutated | 6.9 | Positive | Del(13q) |
| 7.32 × 10−6 | Unmutated | 1.8 | Negative | Negative |
| MRD level . | IGHV-MS . | B2M (mg/L) . | ZAP70 . | FISH subtype . |
|---|---|---|---|---|
| 0.98 × 10−6 detectable | Unmutated | 3.1 | Positive | Negative |
| 0.90 × 10−6 detectable | Unmutated | 5.9 | Positive | Del(11q) |
| Undetectable (limit of detection 1.9 × 10−6) | Unknown | 7.7 | Positive | Trisomy 12 |
| 6.78 × 10−6 | Unmutated | 3.1 | Unknown | Trisomy 12 |
| 5.30 × 10−6 | Unmutated | 3.1 | Positive | Del(11q) |
| 1.87 × 10−6 | Mutated | 6.9 | Positive | Del(13q) |
| 7.32 × 10−6 | Unmutated | 1.8 | Negative | Negative |